A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 240  mg for 12 and 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN/RBV treatment